| ²é¿´: 327 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
byxbľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾ÇóÖú¡¿Çë´ïÈ˰ïæ·ÒëÒ»¾ä¡°ºË´Å¹²Õñ³ÉÏñ¡±Ïà¹ØÓ¢ÎÄ£¬¸ôÐÐÈç¸ôɽ°¡£¬¶àл£¡
|
||
|
Çë´ïÈ˰ïæ·ÒëÒ»¾ä¡°ºË´Å¹²Õñ³ÉÏñ¡±Ïà¹ØÓ¢ÎÄ£¬¸ôÐÐÈç¸ôɽ°¡£¬¶àл£¡ In the two pivotal studies the Primary Efficacy Endpoint,the mean difference in contrast score as assessed from pre to post-contrast images between OptiMARK and Magnevist was 0.018¡À0.061. The lower bound of the two-sided 95% Cl(-0.014) for this difference was superior to the pre-defined non-inferiority margin(¡÷=-0.5). |
» ²ÂÄãϲ»¶
¸É»õ·ÖÏí | Ò»ÎĽ²Í¸Ã¸±êÒÇ¿ÉÌṩµÄ¼ì²âÏîÄ¿£¬ÖµµÃÊղأ¡
ÒѾÓÐ0È˻ظ´
ÏßÁ£Ìå+´úÐ»ÖØ±à³Ì+Ìǽͽâ+×ÔÊÉËÄ´ó¹ú×ÔÈ»ÈȵãÆë¾ÛÒ»ÌÃ
ÒѾÓÐ7È˻ظ´
Éñ¾ÏµÍ³ºÍ¾«Éñ¼²²¡ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ159È˻ظ´
¸É»õ·ÖÏí | ´øÄã¿ìËÙÈëÃÅJAK/STAT signaling pathwaysÐźÅͨ·
ÒѾÓÐ0È˻ظ´
±ê׼ƷºÍ¶ÔÕÕÆ·ÓÐÄÄЩ²»Ò»Ñù£¿
ÒѾÓÐ0È˻ظ´
¸É»õ·ÖÏí | ϸ°û¸´ËÕ¼¼ÇÉ£¬MDL¿ÆÑÐÖúÊÖÀ´Ö§ÕÐ
ÒѾÓÐ0È˻ظ´
¸É»õ·ÖÏí | ÁܰÍϸ°ûºÍNKϸ°û£¬ÊÇÈçºÎÉú³ÉµÄ£¿
ÒѾÓÐ5È˻ظ´
Janus particles £¨ÑÅŬ˹¿ÅÁ££©Î¢ÇòµÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
aids610610
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 259
- Ìû×Ó: 206
- ÔÚÏß: 4.8Сʱ
- ³æºÅ: 614105
- ×¢²á: 2008-09-27
- רҵ: ҽѧ
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
byxb(½ð±Ò+10,VIP+0):¶àл¹þ 10-21 10:52
byxb(½ð±Ò+10,VIP+0):¶àл¹þ 10-21 10:52
|
ÔÚÕâÁ½¸öÖ÷Òª³õ²½ÁÆÐ§Ñо¿µÄÖյ㣬 ÔÚptiMARKºÍÂí¸ùάÏÔÖ®¼äµÄ¶Ô±ÈǰºóµÄͼÏñÆÀ¹ÀÖУ¬Æä¶Ô±ÈÆÀ·ÖµÄƽ¾ù²îÒìΪ0.018 ¡À 0.061¡£ÕâÖÖ²îÒìµÄ˫β95£¥¿ÉÐÅÇø¼ä£¨-0.014£©µÄÏÂÏÞ¸ßÓÚÔ¤¶¨ÒåµÄ·ÇϽ磨¡÷=-0.5£©¡£ ·Òë½²ÇóµÄÊÇÉÏÏÂÎÄÒâ˼£¬Õâλ³æÓÑÓ¦¸Ã¶àÌùµãÎÄÏס£ |
2Â¥2009-10-21 09:49:15
saxon
Ìú³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 195.5
- Ìû×Ó: 87
- ÔÚÏß: 24.8Сʱ
- ³æºÅ: 876359
- ×¢²á: 2009-10-18
- ÐÔ±ð: GG
- רҵ: ´Å¹²Õñ½á¹¹³ÉÏñÓë¼²²¡Õï¶Ï
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
| ´Ë¾äÉæ¼°´Å¹²ÕñרҵµÄÄÚÈÝÊÔÒëÈçÏ£ºÔÚÕâÁ½¸ö¹Ø¼üÑо¿ÖУ¬·Ö±ðÓÃÈû狀ÍÂí¸ùάÏÔ¶Ô±ÈÔöÇ¿£¬Ôöǿǰ¡¢ºóͼÏñ¶Ô±ÈÆÀ·Ö£¬ËüÃÇÖ®¼äµÄƽ¾ù²îÊÇ 0.018¡À0.061¡£Ë«²à95%¿ÉÐÅÇø¼äµÄϽç(-0.014)¸ßÓÚÔ¤¶¨Òå·ÇÁÓÐÔ½çÏÞ(¡÷=-0.5)¡£the Primary Efficacy Endpoint×öÖ÷Óï»ò×´Óï³É·Ö£¿Ò²Çë×÷ÕßΪÎÒ½â»ó¡£ |
3Â¥2009-10-21 13:07:26














»Ø¸´´ËÂ¥